...
首页> 外文期刊>Vaccine >Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses
【24h】

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses

机译:从复制缺陷型单纯疱疹1型载体表达1型人类免疫缺陷病毒诱导抗原特异性T细胞应答

获取原文
获取原文并翻译 | 示例
           

摘要

Herpes simplex type-1 virus (HSV-1) based vectors have been widely used in different gene therapy approaches and also as experimental vaccines against HSV-1 infection. Recent advances in the HSV-1 technology do support the use of replication defective HSV-1 as vaccine vectors for delivery of foreign antigens. We have examined the ability of a recombinant replication-defective HSV-1 vector expressing the HIV-1 Tat protein to induce long-term Tat-specific immune responses in the Balb/c murine model. The results showed that vector administration by the subcutaneous route elicits anti-Tat specific T-cell mediated immune responses in mice characterized by the presence of the Tat-specific cytotoxic activity and production of high levels of IFN-gamma.
机译:基于单纯疱疹1型病毒(HSV-1)的载体已广泛用于不同的基因治疗方法中,也可用作抗HSV-1感染的实验疫苗。 HSV-1技术的最新进展确实支持使用复制缺陷型HSV-1作为递送外来抗原的疫苗载体。我们已经检查了表达HIV-1 Tat蛋白的重组复制缺陷型HSV-1载体在Balb / c鼠模型中诱导长期Tat特异性免疫应答的能力。结果表明,通过皮下途径施用载体在小鼠中引起抗Tat特异性T细胞介导的免疫反应,其特征在于存在Tat特异性细胞毒性活性和高水平的IFN-γ产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号